Which has the lower trailing P/E, TMO or VRTX?

VRTX has the lower trailing P/E: TMO trades at 33.00 and VRTX at 32.13. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, TMO or VRTX?

Over the past five years, VRTX grew revenue faster — TMO at a 5.00% CAGR versus VRTX at 13.57%.

Does TMO or VRTX pay a bigger dividend?

TMO pays a dividend (0.29% yield), while VRTX has no payments in the available dividend history.

Is TMO or VRTX more profitable?

VRTX runs the higher net margin — TMO at 15.06% versus VRTX at 34.89%.

How have TMO and VRTX total returns compared?

Over the past 10 years, TMO delivered 15.19% and VRTX delivered 18.87% annualized total return. Past performance doesn't predict future results.

Thermo Fisher Scientific Inc. (TMO) vs Vertex Pharmaceuticals Incorporated (VRTX)

A side-by-side comparison of Thermo Fisher Scientific Inc. and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 20, 2026. Differences are shown without an overall score or investment verdict.

TMO

Thermo Fisher Scientific Inc.

$228.00B

$613.54HealthcareAt close: Aug 19, 2026, 4:00 PM ET

VRTX

Vertex Pharmaceuticals Incorporated

$140.12B

$552.06HealthcareAt close: Aug 19, 2026, 4:00 PM ET

Total return — TMO vs VRTX

growth of $100 · dividends reinvested · last 10y

TMO +314.4% (+15.3%/yr)VRTX +468.6% (+19.0%/yr)VRTX compounded faster over this window

TMO VRTX

TMO vs VRTX: by the numbers

•TMO is the larger company ($228.00B vs $140.12B market cap).
•VRTX trades at the lower trailing earnings multiple (32.13 vs 33.00 P/E), one valuation lens rather than an overall verdict.
•VRTX converts more revenue to profit (34.89% vs 15.06% net margin).
•VRTX grew revenue faster over the past five years (13.57% vs 5.00% CAGR).
•TMO pays a dividend (0.29% yield), while VRTX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	TMO	VRTX
P/E ratio	33.00	32.13
Forward P/E	24.46	29.41
P/S ratio	4.91	11.18
P/B ratio	4.32	6.97
EV / EBITDA	25.34	26.91
FCF yield	3.22%	2.69%

Profitability

Metric	TMO	VRTX
Gross margin	40.37%	86.04%
Operating margin	17.69%	38.59%
Net margin	15.06%	34.89%
ROE	13.25%	21.76%
ROIC	7.44%	17.33%

Dividends

Metric	TMO	VRTX
Dividend yield	0.29%	N/A
Payout ratio	10.13%	N/A

Growth (annualized)

Metric	TMO	VRTX
Revenue CAGR (5Y)	5.00%	13.57%
EPS CAGR (5Y)	1.99%	8.17%
FCF CAGR (5Y)	-1.83%	16.39%
Total return CAGR (5Y)	2.43%	23.14%

Frequently asked

Which has the lower trailing P/E, TMO or VRTX?: VRTX has the lower trailing P/E: TMO trades at 33.00 and VRTX at 32.13. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, TMO or VRTX?: Over the past five years, VRTX grew revenue faster — TMO at a 5.00% CAGR versus VRTX at 13.57%.
Does TMO or VRTX pay a bigger dividend?: TMO pays a dividend (0.29% yield), while VRTX has no payments in the available dividend history.
Is TMO or VRTX more profitable?: VRTX runs the higher net margin — TMO at 15.06% versus VRTX at 34.89%.
How have TMO and VRTX total returns compared?: Over the past 10 years, TMO delivered 15.19% and VRTX delivered 18.87% annualized total return. Past performance doesn't predict future results.

Go deeper

Full TMO analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

Thermo Fisher Scientific P/E ratio Vertex Pharmaceuticals P/E ratio Thermo Fisher Scientific dividend yield Thermo Fisher Scientific ROE Vertex Pharmaceuticals ROE Thermo Fisher Scientific operating margin Vertex Pharmaceuticals operating margin Thermo Fisher Scientific revenue growth Vertex Pharmaceuticals revenue growth Thermo Fisher Scientific free cash flow Vertex Pharmaceuticals free cash flow

Thermo Fisher Scientific & Vertex Pharmaceuticals appear in these rankings

Highest Operating Margin Stocks Highest 10-Year Total Return Stocks Largest Companies by Market Cap

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 20, 2026.